Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK-423
- Development stage
- Preclinical
- Lead developer
- Akanocure
- Modality
- Small Molecules
01
Overview
AK-423 is a broad-spectrum antiviral and immunomodulatory small molecule agent being developed by Akanocure Pharmaceuticals. It is designed as a dual-action therapeutic for the treatment of severe COVID-19 cases, particularly those involving multiple organ dysfunction. The drug's mechanism involves both the prevention of viral replication and the regulation of the host's immune response to infection, aiming to address the complex abnormal immune signaling that characterizes severe disease. In 2021, the developer received a Phase I research grant from the National Science Foundation (NSF) to support the compound's development as a potential treatment for COVID-19 and future viral pandemic threats.
02
Targets
ACC (Acetyl-CoA Carboxylase 1)
Beyond the preview
Go deeper on AK-423.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK-423.